Refined DRGs: Trials in Europe

Jean L. Freeman

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

DRGs have recently been revised to account for severity of illness through a more refined use of additional diagnoses (comorbidities and complications). Under the refined model, patients are differentiated with respect to classes of additional diagnoses that are disease and procedure specific. The Refined DRGs were evaluated with data from selected Barcelona hospitals and the findings compared to those obtained with Norwegian and English hospital discharge information. In terms of predictive performance, the Refined DRGs represent only a very small improvement over the second revision DRGs for the study's sample of European data. This lack of significant improvement is likely attributed to misclassification of the European discharges due to limited reporting of additional diagnoses. It is recommended that European countries use the Refined DRGs as a descriptive framework for reporting utilization statistics In order to encourage more complete reporting of comorbidities and complications.

Original languageEnglish (US)
Pages (from-to)151-164
Number of pages14
JournalHealth Policy
Volume17
Issue number2
DOIs
StatePublished - 1991
Externally publishedYes

Fingerprint

Diagnosis-Related Groups
Comorbidity

Keywords

  • Misclassification of discharges
  • Predictive performance of RDRGs
  • RDRGs trials In Europe
  • Refined DRGs

ASJC Scopus subject areas

  • Health Policy
  • Public Health, Environmental and Occupational Health

Cite this

Refined DRGs : Trials in Europe. / Freeman, Jean L.

In: Health Policy, Vol. 17, No. 2, 1991, p. 151-164.

Research output: Contribution to journalArticle

Freeman, Jean L. / Refined DRGs : Trials in Europe. In: Health Policy. 1991 ; Vol. 17, No. 2. pp. 151-164.
@article{ef135e6a423345babac8ca48b9526d53,
title = "Refined DRGs: Trials in Europe",
abstract = "DRGs have recently been revised to account for severity of illness through a more refined use of additional diagnoses (comorbidities and complications). Under the refined model, patients are differentiated with respect to classes of additional diagnoses that are disease and procedure specific. The Refined DRGs were evaluated with data from selected Barcelona hospitals and the findings compared to those obtained with Norwegian and English hospital discharge information. In terms of predictive performance, the Refined DRGs represent only a very small improvement over the second revision DRGs for the study's sample of European data. This lack of significant improvement is likely attributed to misclassification of the European discharges due to limited reporting of additional diagnoses. It is recommended that European countries use the Refined DRGs as a descriptive framework for reporting utilization statistics In order to encourage more complete reporting of comorbidities and complications.",
keywords = "Misclassification of discharges, Predictive performance of RDRGs, RDRGs trials In Europe, Refined DRGs",
author = "Freeman, {Jean L.}",
year = "1991",
doi = "10.1016/0168-8510(91)90051-X",
language = "English (US)",
volume = "17",
pages = "151--164",
journal = "Health Policy",
issn = "0168-8510",
publisher = "Elsevier Ireland Ltd",
number = "2",

}

TY - JOUR

T1 - Refined DRGs

T2 - Trials in Europe

AU - Freeman, Jean L.

PY - 1991

Y1 - 1991

N2 - DRGs have recently been revised to account for severity of illness through a more refined use of additional diagnoses (comorbidities and complications). Under the refined model, patients are differentiated with respect to classes of additional diagnoses that are disease and procedure specific. The Refined DRGs were evaluated with data from selected Barcelona hospitals and the findings compared to those obtained with Norwegian and English hospital discharge information. In terms of predictive performance, the Refined DRGs represent only a very small improvement over the second revision DRGs for the study's sample of European data. This lack of significant improvement is likely attributed to misclassification of the European discharges due to limited reporting of additional diagnoses. It is recommended that European countries use the Refined DRGs as a descriptive framework for reporting utilization statistics In order to encourage more complete reporting of comorbidities and complications.

AB - DRGs have recently been revised to account for severity of illness through a more refined use of additional diagnoses (comorbidities and complications). Under the refined model, patients are differentiated with respect to classes of additional diagnoses that are disease and procedure specific. The Refined DRGs were evaluated with data from selected Barcelona hospitals and the findings compared to those obtained with Norwegian and English hospital discharge information. In terms of predictive performance, the Refined DRGs represent only a very small improvement over the second revision DRGs for the study's sample of European data. This lack of significant improvement is likely attributed to misclassification of the European discharges due to limited reporting of additional diagnoses. It is recommended that European countries use the Refined DRGs as a descriptive framework for reporting utilization statistics In order to encourage more complete reporting of comorbidities and complications.

KW - Misclassification of discharges

KW - Predictive performance of RDRGs

KW - RDRGs trials In Europe

KW - Refined DRGs

UR - http://www.scopus.com/inward/record.url?scp=0025806360&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025806360&partnerID=8YFLogxK

U2 - 10.1016/0168-8510(91)90051-X

DO - 10.1016/0168-8510(91)90051-X

M3 - Article

C2 - 10113623

AN - SCOPUS:0025806360

VL - 17

SP - 151

EP - 164

JO - Health Policy

JF - Health Policy

SN - 0168-8510

IS - 2

ER -